H.C. Wainwright raised the firm’s price target on eFfector Therapeutics to $24 from $5 and keeps a Buy rating on the shares. The target adjustment reflects the 1-for-25 reverse stock split of the company’s common stock. The firm now expects Effector’s cash runway to take it into Q1 of 2025, “past two important data milestones.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EFTR:
- eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
- eFFECTOR Therapeutics Regains Nasdaq Compliance Status
- eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- eFFECTOR Therapeutics Secures $15M in Direct Offering
- eFfector to sell 1.49M shares at $10.075 in registered direct offering